Behind the science
'Organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer'
The future is here – and scientists at GSK are already using digital biological twins and organoids to create personalised solutions for patients with cancer. Here, Professor Tony Ng, who runs GSK’s Translational Oncology Research Hub, explains how they work – and the first of its kind trial his team are running to map out detailed replicas of lung cancer tumours for 200 NHS patients.
Our purpose
We are a focused biopharma company with strong momentum and big ambitions, to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of the decade, as a successful, growing company where people can thrive.Our R&D focus is on four therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases.
Behind the science
Discover how we're getting ahead
Life at GSK
Find out what it's like to work with us
Make a difference with us
Do your best work with us
Be yourself with us
